Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his ...

Pfizer Inc's antiviral treatment Paxlovid reduces COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, according to a new study in Israel conducted ...

And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...

Pfizer had previously estimated sales of Paxlovid on the year to only reach $8 billion, as demand for Covid vaccines and treatment wanes and the World Health Organization said the pandemic is ...

Pfizer stands to make a huge amount of money from Paxlovid. The investment bank SVB Leerink estimated that the drug would bring in $24 billion in global revenue in 2022 and $33 billion in 2023.

Pfizer boosted its profit outlook for the year following gains to its top- and bottom-line in its latest quarter.

Pfizer announced on Thursday it has reached an agreement to supply up to six million courses of its COVID-19 antiviral Paxlovid to the Global Fund to get treatment to low and middle-income ...